Journal Watch: Fat Perception; Statin-Induced Diabetes; Improving Beta-Cell Function

We know you don’t have time to read it all.  Here are some of the studies that caught our eye this week.

Dessert Doesn’t Taste the Same for Obese Smokers

Women who are both obese and smokers may have less fat perception than smokers of normal weight or obese and normal-weight non-smokers. Subjects were given puddings and were asked to rate them based on creaminess and sweetness. Results showed that compared to the other groups, obese smokers derived less pleasure from the desserts. A compromised ability to perceive fat and sweetness may contribute to more fat intake in a group already at risk for metabolic and cardiovascular disease.

Original source: Obesity

Statins and the Risk of Diabetes Development

Statins, especially high-dose statins, have been shown to increase the risk of developing diabetes in patients predisposed to the disease. But should this risk preclude the use of statins in this patient population? This study evaluates the possible mechanism by which statins increase the risk of type 2 diabetes development and what factors (ie, statin dose/properties, patient characteristics) influence greater risk. The authors conclude that while an increase in diabetes risk exists, this increase is small enough where the risk does not outweigh the benefit of the potential reduction in cardiovascular events.

Original Source: Obesity

Alogliptin/Pioglitazone Combo on Beta-Cell Function

Does the use of alogliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, in combination with pioglitazone, a thiazolidinedione, help to slow the progression of beta-cell function decline in patients with type 2 diabetes? In the clinical trial, patients were given either this combination or alogliptin monotherapy. Results show that that while both therapies improved glycemic control, only the combination of alogliptin/pioglitazone improved beta-cell function.

Original Source: European Journal of Endocrinology